Adaptix Ltd is a technology company.
Adaptix Ltd is a technology company.
Adaptix Ltd has raised $6.0M across 2 funding rounds.
Adaptix Ltd has raised $6.0M in total across 2 funding rounds.
Adaptix Ltd has raised $6.0M in total across 2 funding rounds.
Adaptix Ltd's investors include Par Equity.
# Adaptix Ltd: Transforming Medical Imaging Through 3D X-ray Technology
Adaptix Ltd is a medical imaging technology company developing portable, low-dose 3D X-ray imaging solutions designed to make advanced diagnostics more accessible and affordable.[1][2] The company's core product enables 3D X-ray imaging at doses and costs comparable to traditional 2D X-rays, addressing a fundamental challenge in radiology: delivering high-quality diagnostic imaging without the expense, radiation exposure, or infrastructure limitations of current systems.[2]
The company serves hospitals, clinics, and remote care settings globally, targeting healthcare providers who need diagnostic imaging capabilities but face constraints around cost, portability, or patient safety.[2][3] Adaptix's mission centers on making "3D-first" imaging the standard of care by removing barriers to access—whether geographic, financial, or technical—so that patients everywhere can receive superior diagnostics when and where they need them.[2][3]
Adaptix was founded by leading experts in radiation production, medical devices, and technology transfer, bringing deep domain expertise to the imaging challenge.[1][2] The company is headquartered at Oxford University's Begbroke Science Park in the UK,[1] positioning it within a research-intensive ecosystem that has likely informed its technical development.
The founding team assembled specialists across hardware and software engineering, business strategy, and product leadership—a deliberate composition reflecting the complexity of bringing medical imaging innovation to market.[2] While specific founding dates and individual founder names are not detailed in available sources, the team's background in both radiation science and medical device commercialization suggests the company emerged from recognizing a gap between existing imaging capabilities and clinical needs: the ability to deliver 3D imaging safely and affordably at the point of care.
Adaptix operates at the intersection of several powerful trends reshaping healthcare. The global push toward point-of-care diagnostics is reducing reliance on centralized imaging centers, particularly in underserved regions. Simultaneously, healthcare cost pressures are driving demand for solutions that deliver clinical value without proportional increases in infrastructure spending.
The company's technology also aligns with broader movements toward lower-dose medical imaging and AI-enabled diagnostics—trends driven by both patient safety concerns and the recognition that 3D data enables more sophisticated analysis than traditional 2D imaging. In industrial applications beyond healthcare, the technology addresses similar needs for non-destructive testing and inspection.
Adaptix's location within the UK's advanced manufacturing and medtech ecosystem, combined with its focus on making imaging more accessible globally, positions it to influence how diagnostic imaging evolves in resource-constrained settings—a significant portion of the world's healthcare infrastructure.
Adaptix is solving a genuine problem at an opportune moment: healthcare systems worldwide are simultaneously seeking to improve diagnostic quality, reduce costs, and expand access. The company's ability to deliver 3D imaging without the traditional penalties of dose, cost, or complexity addresses all three imperatives.
The path forward likely involves clinical validation across additional applications beyond breast imaging, regulatory clearances in key markets, and scaling manufacturing to meet global demand. Success will depend on demonstrating that the technology integrates seamlessly into existing clinical workflows and delivers measurable improvements in diagnostic confidence and patient outcomes.
If Adaptix executes effectively, it could reshape expectations around what imaging capabilities should be available at the point of care—making advanced diagnostics a standard feature of primary care rather than a specialized service, with ripple effects across healthcare delivery globally.
Adaptix Ltd has raised $6.0M across 2 funding rounds. Most recently, it raised $2.0M Venture Round in January 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2019 | $2.0M Venture Round | Par Equity | |
| Aug 1, 2017 | $4.0M Venture Round | Par Equity |